RCUS
Arcus Biosciences Inc
24.50$
+1.0%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | +666.9% | +0.0% | +0.0% | +243.3% | -63.6% | +12.0% | +0.0% | +0.0% | +457.1% | -82.1% | +0.0% | +3,587.4% | -85.3% | -0.3% | +0.0% | +0.0% | +3,647.0% | -94.9% | +50.0% | +22.2% | +2.0% | -25.7% | +16.0% | +10.3% | -3.1% | +367.7% | -73.1% | +23.1% | -45.8% | +7.7% | +471.4% | -83.8% | +26.9% | -48.5% | +141.2% | – | |
| – | -59.3% | +35.0% | +173.6% | -43.3% | -4.1% | +17.6% | -6.1% | -11.1% | +36.0% | +60.7% | -31.0% | +20.0% | +11.9% | +54.2% | +45.1% | -6.0% | +36.3% | +3.6% | +3.6% | -96.5% | +38.8% | +2.8% | +2.3% | -5.0% | +16.7% | +0.0% | -25.0% | +66.7% | -40.0% | -33.3% | – | – | – | – | +0.0% | +50.0% | -33.3% | – | – | |
| – | – | – | – | +666.9% | +0.0% | +0.0% | +243.3% | -63.6% | +12.0% | +0.0% | +0.0% | +457.1% | -82.1% | +0.0% | +3,587.4% | -85.3% | -0.3% | +0.0% | +0.0% | +3,647.0% | -94.9% | +50.0% | +22.2% | +2.0% | -25.7% | +16.0% | +10.3% | -3.1% | +367.7% | -73.1% | +23.1% | -45.8% | +7.7% | +471.4% | -85.0% | +25.0% | -50.0% | +173.3% | – | |
| – | -59.3% | +35.0% | +173.6% | -43.3% | -4.1% | +17.6% | -6.1% | -11.1% | +36.0% | +60.7% | -31.0% | +20.0% | +11.9% | +54.2% | +45.1% | -6.0% | +36.3% | +3.6% | +3.6% | -29.9% | +22.2% | +14.8% | +10.0% | +4.2% | +1.0% | +3.7% | -2.4% | +13.4% | +17.2% | +5.5% | +7.0% | -17.9% | +20.8% | +13.9% | +1.4% | -14.2% | +0.8% | -7.4% | – | |
| – | -91.1% | +22.3% | +1.7% | +31.5% | +19.6% | +17.8% | +3.7% | +0.9% | +37.6% | +19.0% | +31.2% | -15.0% | +6.3% | +63.1% | -2.2% | +14.4% | +23.7% | +6.4% | -2.9% | +42.5% | +3.0% | +8.3% | +0.0% | +7.3% | +7.5% | -6.7% | +7.1% | -3.3% | +10.3% | -6.3% | +0.0% | -6.7% | +0.0% | +3.6% | -6.9% | -3.7% | +11.5% | -17.2% | – | |
| – | -59.9% | +32.4% | +141.1% | -37.4% | -0.1% | +17.6% | -4.2% | -8.5% | +36.4% | +50.6% | -19.1% | +9.1% | +10.5% | +56.3% | +33.6% | -2.3% | +33.7% | +4.1% | +2.3% | -16.4% | +16.1% | +12.9% | +7.3% | +4.9% | +2.7% | +0.9% | +0.0% | +8.9% | +32.0% | -9.9% | +5.5% | -15.7% | +16.3% | +12.0% | -1.2% | -13.3% | +3.5% | -8.1% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -3,451.3% | – | – | – | – | -123.8% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +50.4% | +155.8% | -46.5% | +5.2% | +77.6% | -100.0% | – | +100.0% | -50.0% | -100.0% | – | +100.0% | -50.0% | +100.0% | +50.0% | +366.7% | -78.6% | +0.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -2,945.9% | – | – | – | – | -123.8% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -122.8% | – | – | -44.9% | -335.0% | – | – | – | -50.0% | +100.0% | -50.0% | +0.0% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -2,945.9% | – | – | – | – | -124.3% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -2,066.8% | – | – | – | – | -123.2% | – | – | – | – | – | – | – | – | -1,400.0% | – | – | – | – | -3,350.0% | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.